Short Interest in Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) Expands By 120.7%

Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) was the target of a large growth in short interest in July. As of July 15th, there was short interest totaling 3,746,865 shares, a growth of 120.7% from the June 30th total of 1,697,593 shares. Approximately 9.6% of the company’s stock are short sold. Based on an average trading volume of 686,566 shares, the days-to-cover ratio is presently 5.5 days.

Wall Street Analyst Weigh In

Separately, Wall Street Zen cut Coeptis Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Coeptis Therapeutics Trading Down 8.6%

NASDAQ ZSQR opened at $4.81 on Tuesday. The stock has a market capitalization of $247.38 million, a price-to-earnings ratio of -1.91 and a beta of -0.25. The stock’s 50 day moving average price is $9.78 and its two-hundred day moving average price is $11.65. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.25 and a current ratio of 3.25. Coeptis Therapeutics has a 52 week low of $4.32 and a 52 week high of $21.41.

Coeptis Therapeutics (NASDAQ:ZSQR) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.65) earnings per share for the quarter. The firm had revenue of $0.11 million for the quarter. Coeptis Therapeutics had a negative return on equity of 92.29% and a negative net margin of 810.04%.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its position in Coeptis Therapeutics by 12.6% in the fourth quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock valued at $600,000 after purchasing an additional 4,721 shares in the last quarter. State Street Corp lifted its position in Coeptis Therapeutics by 35.0% during the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after buying an additional 6,962 shares in the last quarter. Marshall Wace LLP bought a new stake in Coeptis Therapeutics during the 4th quarter worth about $259,000. Finally, Steward Partners Investment Advisory LLC boosted its stake in shares of Coeptis Therapeutics by 100.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock worth $71,000 after buying an additional 2,500 shares during the last quarter. Institutional investors and hedge funds own 13.88% of the company’s stock.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.